How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about isatuximab

Marketing authorisation indication/anticipated marketing authorisation indication

2.1

Isatuximab (Sarclisa, Sanofi) is indicated 'in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy'.

Price

2.3

The list prices for isatuximab per 500-mg vial (excluding VAT; BNF online, accessed January 2024) are:

  • £506.94 per 100 mg/5 ml solution for infusion vial

  • £2,534.69 per 500 mg/25 ml solution for infusion vial

2.4

The company has a commercial arrangement, which would have applied if isatuximab had been recommended.